Clinical Trial Detail

NCT ID NCT03568539
Title IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Innovent Biologics (Suzhou) Co. Ltd.
Indications

urinary bladder cancer

prostate cancer

colorectal cancer

melanoma

stomach cancer

endometrial cancer

lung non-small cell carcinoma

lung small cell carcinoma

Therapies

Sintilimab

Age Groups: senior adult

No variant requirements are available.